Rahmanian K, Shakeri M, Rahmanian V, Najafi-Tireh SS, Fatemeh SJ, Abdolreza SJ

Language: English
References: 21
Page: 54-59
PDF size: 295.96 Kb.

ABSTRACT

Splenectomy is necessary in beta thalassemia major patients when the spleen becomes hyperactive, leading to extreme destruction of erythrocytes. This study assessed the ferritin effect on serum pneumococcal antibody response following pneumococcal vaccination, in patients with beta thalassemia major after splenectomy. In this case series study, convenience sampling was used to recruit 347 splenectomised beta thalassemia patients under the auspices of Jahrom University of Medical Sciences. Demographic data such as age, sex, and time after splenectomy were recorded by a questionnaire. All participants had been splenectomised and received a dose of Pneumovax1 23 vaccine 14 days before surgery. The IgG antibody responses to pneumococcal vaccine and levels of serum specific ferritin were determine by commercial enzyme immunoassay kits. For the analysis, SPSS software version 16 was used. A p-value less than 0.05 was considered statistically significant. Most of the participants (63.4%) were hypo-responders to pneumococcal vaccine. Also, serum anti-pneumococcal IgG antibody was related to post splenectomy duration and serum ferritin (p< 0.001), but not to gender (p> 0.05). An important result was a relation of serum anti-pneumococcal IgG antibody to serum ferritin according to post splenectomy duration groups. Therefore, in three groups of post splenectomy duration, the serum ferritin was higher in hypo-responder than in good responder subjects. Our results indicate that serum anti-pneumococcal IgG antibody decreased with increment of serum ferritin and post splenectomy duration. Thus, there is a need to re-address the approach towards revaccination in this immune-compromised group of patients by administering a booster pneumococcal vaccination in an attempt to recover immunity and reduce morbidity.

REFERENCES

1. Weatherall D, Clegg J. The Thalassaemia Syndromes. Oxford: Blackwell Scientific Publications; 2001.

2. Ali D, Mehran K, Moghaddam AG. Comparative evaluation of renal findings in Beta-thalassemia major and intermedia. Saudi J Kidney Dis Transpl. 2008;19(2):206-9.

3. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-88.

4. Ricerca BM, Di Girolamo A, Rund D. Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hemat Infect Dis. 2009;1(1):e2009028.

5. Cadili A, de-Gara C. Complications of splenectomy. Amer J Med. 2008;121(5):371-5.

6. Jahromi AS, Rahmanian K. Natural Immunity Against Haemophilus influenza Type B in Children, South of Iran: Need for Vaccination. Pak J Biol Sci. 2012;15(3):160-3.

7. Austrian R. Pneumococcal infection and pneumococcal vaccine. N Engl J Med. 1977; 297:938-9

8. Jahromi AS, Farjam MR, Makarem A, Karami MY, Amanat A, Madani A. Immunity to Pneumococcal Vaccine in Splenectomized ß-Thalassemia Patients. American J Immunol. 2012;8(2):33-7.

9. Jahromi AS, Rahmanian K, Davami MH, Zabetian H, Yusefi A, Madani A. Natural Immunity Against Haemophilus influenza Type B in Splenectomised Beta-thalassemia Children. Pak J Biol Sci. 2014;17(11):1190-4.

10. Shander A, Cappellini M, Goodnough L. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox sang. 2009;97(3):185-97.

11. Ghaffari J, Vahidshahi K, Kosaryan M, Soltantooyeh Z, Mohamadi M. Humoral immune system state in ß thalassemia major. Med Glas (Zenica). 2011;8(2):192-6.

12. Aleem A, Shakoor Z, Alsaleh K, Algahtani F, Iqbal Z, Al-Momen A. Immunological Evaluation of b-Thalassemia Major Patients Receiving Oral Iron Chelator Deferasirox. J Coll Physicians Surg Pak. 2014;24 (7):467-71.

13. Walker EM Jr, Walker SM. Review: Effects of Iron Overload on the Immune System. Ann Clin Lab Sci. 2000;30(4):354-65.

14. Pardalos G, Kanakoudi-Tsakalidis F, Malaka-Zafiriu M, Tsantali H, Athanasiou-Metaxa M, Kallinikos G, et al. Iron-related disturbances of cell-mediated immunity in multitransfused children with thalassemia major. Clin Exp Immunol. 1987;68:138-45.

15. Zarina AL, Norazlin KN, Hamidah A, Aziz DA, Zulkifli SZ, Jamal R. Spectrum of infections in splenectomised thalassaemia patients. Medical J Malaysia. 2010;65(4):283-5.

16. Sakran W, Levin C, Kenes Y, Colodner R, Koren A. Clinical spectrum of serious bacterial infections among splenectomized patients with hemoglobinopathies in Israel: a 37-year follow-up study. Infection. 2012;40(1):35-9.

17. Rao SP, Rajkumar K, Schiffman G, Desai N, Unger C, Miller ST. Anti-pneumococcal antibody levels three to seven years after first booster immunization in children with sickle cell disease, and after a second booster. Journal Pediatr. 1995;127(4):590-2.

18. Orthopoulos GV, Theodoridou MC, Ladis VA, Tsousis DK, Spoulou VI. The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with ß-thalassemia. Vaccine. 2009;27(3):350-4.

19. Jahromi AS, Raoofi R, Sarikhani M, Madani A. Evaluation of anti-tetanus immunity in haemodialysis patients. Am J Immunol. 2009;5:108-12.

20. Jahromi AS, Pourahmd M, Azhdari S, Manshoori G, Madani A, Moosavy SH. Immunity to diphtheria in haemodialysis patients. Am J Infect Dis. 2011;7:20-3.

21. Bazi A, Shahramian I, Yaghoobi H, Naderi M, Azizi H. The Role of Immune System in Thalassemia Major: A Narrative Review. J Pediatr Rev. 2018;6(2):e14508.doi:https:/10.5812/jpr.14508.